Company Overview
Company Type: Private Company
Website: www.cambrex.com
Global Number of Employees (Latest): 1,732
Year Founded: 1981


Business Description
Cambrex Corporation operates as a life sciences company that provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as finished dosage forms. The company caters to generic drug companies and companies that discover and commercialise small-molecule human therapeutics. The company sells its products directly as well as through independent agents. Cambrex Corporation was founded in 1981 and is based in East Rutherford, New Jersey with an additional office in Charles, Iowa.

Financial Information (Currency: CAD, in mm) 
Total Revenue
840.6
Market Capitalization
2,751.7
EBITDA
217.8
EBIT
139.4
Cash & ST Invst.
109.9
P/Diluted EPS Before Extra
56.7x
Net Income
50.0
Total Debt
731.8
Price/Tang BV
91.7x
Capital Expenditure
(87.9)
Total Assets
2,049.1
Total Debt/EBITDA
3.2x
U.S. Number of Employees 2022
1,221
U.S. Number of Employees 2021
1,120
U.S. Last Year Employee Growth %
9.0
Currency in CAD in mm, LTM as of Sep-30-2019 TEV and Market Cap are calculated using a close price as of Dec-03-2019

Key Professionals
Name
Title
Loewald, Thomas W.
CEO & Executive Director
Green, Robert Charles
Executive VP & CFO
Hanley, Samantha M.
Senior VP, General Counsel & Corporate Secretary
Maw, Alex 
Senior Director of Marketing & Communications
Brienza, Dorothy Donnelly
Senior VP & Chief Human Resources Officer
Biscaro, Bruno 
President of Drug Products
Edwards, Simon 
President of CDMO Sales & Marketing
Ferrante, Frank 
Chief Mergers & Acquisitions Officer
Fincher, Brandon 
Chief Strategy Officer
Haitz, Stephan 
President of CDMO Sales & Marketing
Nettleton, Joe 
President of Drug Substance
Player, Troy 
President of Early Stage Development & Testing

Key Board Members
Name
Title
Hewett, Wayne M.
Chairman
Loewald, Thomas W.
CEO & Executive Director
Coyle, John 
Director
Glassell, Claes 
Director
Minello, Henry
Director
O’Donnell, Laura 
Director


Primary Industry Classification
Life Sciences Tools and Services


Primary Office Location
One Meadowlands Plaza | East Rutherford, NJ | 07073 | United States
Phone: 201 804 3000   Fax: 201 804 9852

Current and Pending Investors
Investor
Initial Investment Date
Stake Type
Current Stake Amount
Round(s)
Investment Coverage
Permira Advisers Ltd.
Aug-07-2019
Majority
100.00 %
-
Henry Minello, John Coyle, Laura O'Donnell, Raz Khan

Prior Investors
BlackRock, Inc. (NYSE:BLK), Endeavor Capital Management, GAMCO Investors, Inc. (OTCPK:GAMI), Royce & Associates, LP, The Vanguard Group, Inc., William Blair Investment Management, LLC


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Snapdragon Chemistry, Inc.
Snapdragon Chemistry, Inc. engages in developing continuous flow chemistry solutions for the discovery and production of active pharmaceutical ingredients, intermediates, and materials. It offers process development, reactor design and build, portfolio optimization, and GMP manufacturing services. The company develops processes to solve chemistry problems of pharmaceutical, chemical, animal care, and material science companies. Snapdragon Chemistry, Inc. was formerly known as Firefly Chemistry, Inc. and changed its name to Snapdragon Chemistry, Inc. in April 2015. The company was incorporated in 2014 and is based in Waltham, Massachusetts. As of January 18, 2023, Snapdragon Chemistry, Inc. operates as a subsidiary of Cambrex Corporation.

United States and Canada
Research and Consulting Services
5.00
-
-
Q1 Scientific Limited
Q1 Scientific Limited offers environmentally controlled storage services for pharmaceutical, medical devices, and life sciences industries. The company was incorporated in 2012 and is based in Waterford, Ireland.

Europe
Environmental and Facilities Services
-
-
-
Avista Pharma Solutions, Inc.
Avista Pharma Solutions manufactures drug substance and drug products. The company was founded in 2015 and is based in Lafayette, Colorado. As of January 2, 2019, Avista Pharma Solutions operates as a subsidiary of Cambrex Corporation.

United States and Canada
Pharmaceuticals
62.00
66.00
27.00
Halo Pharma, Inc./8121117 Canada Inc./Halo Pharmaceutical Canada Inc.
As of September 12, 2018, Halo Pharma, Inc./8121117 Canada Inc./Halo Pharmaceutical Canada Inc. was acquired by Cambrex Corporation. Halo Pharma, Inc. and 8121117 Canada Inc. and Halo Pharmaceutical Canada Inc. represents the combined operations of Halo Pharma, Inc. and 8121117 Canada Inc. and Halo Pharmaceutical Canada Inc. in their sale to Cambrex Corporation. Halo Pharma, Inc. and Halo Pharmaceutical Canada Inc. provides pharmaceutical contract development and manufacturing services. Halo Pharma, Inc. is based in the United States. 8121117 Canada Inc. and Halo Pharmaceutical Canada Inc. are based in Canada.

United States and Canada
Pharmaceuticals
-
-
-
Cambrex High Point, Inc.
Cambrex High Point, Inc. specializes in developing, manufacturing, and scaling up small molecule APIs for clinical phase projects. The company provides custom synthesis, process development, GMP manufacturing, and other chemistry services for biotechnology and pharmaceutical companies. It performs various chemistry services, including custom organic synthesis, cGMP scale-up, non GMP and GMP API manufacturing, controlled substance research and development and manufacturing, chemical process research and development, and analytical services. Cambrex High Point, Inc. was formerly known as PharmaCore, Inc. and changed its name to Cambrex High Point, Inc. in October 2016. The company was founded in 1999 and is based in High Point, North Carolina. As of October 7, 2016, Cambrex High Point, Inc. operates as a subsidiary of Cambrex Corporation.

United States and Canada
Life Sciences Tools and Services
38.00
-
-
51% stake in Zenara Pharma Limited and Cambrex Zenara
As of November 2, 2010, 51% stake in Zenara Pharma Limited and Cambrex Zenara were acquired by Cambrex Corp. 51% stake in Zenara Pharma Limited and Cambrex Zenara represents the combined operations of Zenara Pharma Limited and Cambrex Zenara in their sale to Cambrex Corp. Zenara Pharma Limited develops, manufactures, and supplies pharmaceutical products. Cambrex Zenara engages in pharmaceutical drug production, formulation, development, and manufacturing. Zenara Pharma Limited is based in London, United Kingdom and Cambrex Zenara is based in Hyderabad, India.

Asia / Pacific
Pharmaceuticals
-
-
-
Marathon Biopharmaceuticals
As of October 30, 2001, Marathon Biopharmaceuticals was acquired by Cambrex Corporation. Marathon Biopharmaceuticals is a full service, contract manufacturing company. It manufacturers biopharmaceutical ingredients and purified bulk biologics for pre-clinical evaluation, clinical trials, and commercial scale quantities. The company is headquartered in Hopkinton, Massachusetts.

United States and Canada
Life Sciences Tools and Services
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Nov-21-2022
Jan-18-2023
Merger/Acquisition
Buyer
Snapdragon Chemistry, Inc.
Cambrex Corporation

-
Jun-01-2022
Jun-01-2022
Merger/Acquisition
Buyer
Q1 Scientific Limited
Cambrex Corporation

-
Aug-07-2019
Dec-04-2019
Merger/Acquisition
Target
Cambrex Corporation
Permira Advisers Ltd.
BlackRock, Inc. (NYSE:BLK),The Vanguard Group, Inc.,William Blair Investment Management, LLC
2,604.54
Nov-20-2018
Jan-02-2019
Merger/Acquisition
Buyer
Avista Pharma Solutions, Inc.
Cambrex Corporation
Ampersand Capital Partners (nka:Ampersand Management LLC)
328.82
Jul-23-2018
Sep-12-2018
Merger/Acquisition
Buyer
Halo Pharma, Inc./8121117 Canada Inc./Halo Pharmaceutical Canada Inc.
Cambrex Corporation
SK Capital Partners, LP
425.00
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Oct-02-2023
Company Conference Presentations
Cambrex Corporation Presents at 2023 PDA Pharmaceutical Microbiology Conference, Oct-02-2023
Sep-21-2023
Company Conference Presentations
Cambrex Corporation Presents at 22nd Annual Contract Pharma Contracting & Outsourcing Conference, Sep-21-2023
Sep-20-2023
Company Conference Presentations
Cambrex Corporation Presents at BIOMEDevice Boston 2023, Sep-20-2023
Sep-06-2023
Company Conference Presentations
Cambrex Corporation Presents at Pharma ChemOutsourcing 2023, Sep-06-2023
Jun-05-2023
Company Conference Presentations
Cambrex Corporation Presents at BIO International Convention 2023, Jun-05-2023

Competitors
Abcam, Inc., Akzo Nobel N.V. (ENXTAM:AKZA), Alexion Pharmaceuticals, Inc., Almac Group Limited, Amphastar Pharmaceuticals, Inc. (NasdaqGS:AMPH), ANI Pharmaceuticals, Inc. (NasdaqGM:ANIP), Arkema Inc., Assertio Holdings, Inc. (NasdaqCM:ASRT), BASF Corporation, Biogen Inc. (NasdaqGS:BIIB), Catalent, Inc. (NYSE:CTLT), Charles River Laboratories International, Inc. (NYSE:CRL), Codexis, Inc. (NasdaqGS:CDXS), Covidien plc (Acquired), Curia Global, Inc., Dr. Reddy's Laboratories Limited (BSE:500124), Eurofins Scientific SE (ENXTPA:ERF), Evotec SE (XTRA:EVT), Francopia S.A.R.L., Genentech, Inc., ICON Public Limited Company (NasdaqGS:ICLR), Illumina, Inc. (NasdaqGS:ILMN), IQVIA Holdings Inc. (NYSE:IQV), Johnson Matthey Plc (LSE:JMAT), K+S Aktiengesellschaft (XTRA:SDF), Labcorp Drug Development Inc., LANXESS Corporation, Life Technologies Corporation, Lonza Group AG (SWX:LONN), Medtronic plc (NYSE:MDT), Noramco, Inc., Novozymes A/S (CPSE:NZYM B), Parexel International Corporation, Patheon N.V., Pharmaceutical Product Development, LLC, Piramal Enterprises Limited (BSE:500302), PRA Health Sciences, Inc., Prestige Consumer Healthcare Inc. (NYSE:PBH), Quest Diagnostics Incorporated (NYSE:DGX), Quotient Sciences Limited, Rhodia S.A., Roche Holding AG (SWX:ROG), Shanghai SynTheAll Pharmaceutical Co., Ltd., Siegfried Holding AG (SWX:SFZN), Sigma-Aldrich Corporation, STEMCELL Technologies Canada Inc., Supernus Pharmaceuticals, Inc. (NasdaqGM:SUPN), Syneos Health, Inc., Thermo Fisher Scientific Inc. (NYSE:TMO), Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX), WuXi AppTec Co., Ltd. (SHSE:603259), WuXi PharmaTech (Cayman) Inc.

M&A Advisors
AZB & Partners, Banc of America Securities LLC, Bear, Stearns & Co. Inc., Debevoise & Plimpton LLP, Fasken Martineau DuMoulin LLP, Freshfields Bruckhaus Deringer LLP, Gowling WLG (UK) LLP, Kirkland & Ellis LLP, Milbank LLP, Morgan Stanley & Co. LLC, RBC Capital Markets, LLC, Ropes & Gray LLP, Wells Fargo Securities, LLC, Wertheim Schroder & Co. Inc


Advisors
Most Recent Auditor
BDO LLP
M&A Advisors
AZB & Partners, Banc of America Securities LLC, Bear, Stearns & Co. Inc., Debevoise & Plimpton LLP, Fasken Martineau DuMoulin LLP, Freshfields Bruckhaus Deringer LLP, Gowling WLG (UK) LLP, Kirkland & Ellis LLP, Milbank LLP, Morgan Stanley & Co. LLC, RBC Capital Markets, LLC, Ropes & Gray LLP, Wells Fargo Securities, LLC, Wertheim Schroder & Co. Inc
Key development Advisor
Bear, Stearns & Co. Inc.


Most Recent Auditor
BDO LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
MarketLine

Sep 30, 2023 06:01 AM
Cambrex Corporation
Cambrex Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
Reports
32
GlobalData

Sep 22, 2023 12:39 AM
Cambrex Corporation
Cambrex Corp
Reports
379
Quant IP GmbH
Quant IP Research Team
Sep 13, 2023 06:00 PM
Cambrex Corporation
Quant IP Competitive Technology Report Cambrex-Corporation 2023-09-01
Reports
31
GlobalData

Aug 18, 2023 03:45 AM
Cambrex Corporation
Cambrex Corp - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
52
Quant IP GmbH
Quant IP Research Team
Jul 09, 2023 06:00 PM
Cambrex Corporation
Quant IP Competitive Technology Report Cambrex-Corporation 2023-07-01
Reports
31
GlobalData

Jun 20, 2023 01:38 AM
Cambrex Corporation
Cambrex Corp
Reports
379
Quant IP GmbH
Quant IP Research Team
Jun 16, 2023 06:00 PM
Cambrex Corporation
Quant IP Competitive Technology Report Cambrex-Corporation 2023-06-01
Reports
31
GlobalData

May 17, 2023 06:27 AM
Cambrex Corporation
Cambrex Corp - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
52
Quant IP GmbH
Quant IP Research Team
May 13, 2023 06:00 PM
Cambrex Corporation
Quant IP Competitive Technology Report Cambrex-Corporation 2023-05-01
Reports
31
GlobalData

Mar 15, 2023 12:26 AM
Cambrex Corporation
Cambrex Corp
Reports
377



Top Buyers
Buyers
Common Stock Equivalent Held
Change
Toroso Investments, LLC
0
1,995

Top Sellers
Sellers
Common Stock Equivalent Held
Change
Water Island Capital, LLC
0
(202,177)
Confluence Investment Management LLC
0
(110,952)
Grantham Mayo Van Otterloo & Co. LLC
0
(18,529)
Analytic Investors, LLC
0
(5,885)
Morningstar Investment Management LLC
0
(3,901)


S&P Global Ratings Credit Ratings
Debt Type (Rating Type)
Current Rating
Rating Date
Current CreditWatch / Outlook
Current CreditWatch / Outlook Date
Issuer Credit Rating (Local Currency LT)
B
Nov-05-2019
Stable
11/5/2019 7:03:03 PM
Issuer Credit Rating (Foreign Currency LT)
B
Nov-05-2019
Stable
11/5/2019 7:03:03 PM


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
Active Pharmaceutical Ingredients, Benzoyl Peroxide, Biotherapeutic Media and Serum Products, Cell Based Assays, Cell Biology Products, Cell Therapy Services, Crop Protection Product, Endotoxin and Mycoplasma Detection Products, Feed Additive Products, Fine Chemicals, Molecular Biology Products, Pharmaceutical Intermediates Products, X-ray Media


Upcoming Events
Date/Time
Type
Oct-22-2023
Company Conference Presentations
Oct-22-2023
Conferences
Oct-24-2023
Company Conference Presentations
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Reporting Owner(s)
Source
Form Type
Size
Dec-05-2019
Dec-04-2019
Cambrex Corporation

SEC
8-K (1.02, 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 7.01, 9.01)
334 KB
Dec-04-2019
-
Cambrex Corporation
NEW YORK STOCK EXCHANGE LLC
SEC
25-NSE
4 KB
Oct-31-2019
Sep-30-2019
Cambrex Corporation

SEC
10-Q
11 MB
Oct-24-2019
Oct-23-2019
Cambrex Corporation

SEC
8-K (2.02, 5.07, 9.01)
209 KB
Oct-17-2019
-
Cambrex Corporation

SEC
DEFA14A
26 KB
Oct-17-2019
Oct-15-2019
Cambrex Corporation

SEC
8-K (8.01)
157 KB
Oct-15-2019
-
Cambrex Corporation

SEC
DEFA14A
81 KB
Oct-15-2019
Oct-15-2019
Cambrex Corporation

SEC
8-K (8.01)
247 KB
Sep-23-2019
-
Cambrex Corporation

SEC
DEFM14A
2 MB
Sep-23-2019
-
Cambrex Corporation

SEC
DEFA14A
32 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Glassell M.Sc., Claes  (Director)
Dec-04-2019
Common Stock
(7,936)
(126,816)
Derivative Exercise and Sale
-
Form 4
-
Dec-04-2019
Common Stock
1,613
98,988
Derivative Exercise
-
Form 4
-
Dec-04-2019
Common Stock
1,577
126,508
Derivative Exercise
-
Form 4
-
Dec-04-2019
Common Stock
1,980
144,617
Derivative Exercise
-
Form 4
-
Dec-04-2019
Common Stock
2,766
150,711
Derivative Exercise
-
Form 4
-
Dec-04-2019
Common Stock
(7,936)
(647,640)
Sale
-
Form 4
Glassell M.Sc., Claes  (Director)
Dec-04-2019
Common Stock
(6,161)
(502,786)
Open Market Disposition
(100.00)
Form 4
Klosk B.S., J.D., Steven M. (Former CEO & Director)
Dec-04-2019
Common Stock
168,000
10,123,407
Derivative Exercise and Retained Stock
(100.00)
Form 4
-
Dec-04-2019
Common Stock
50,000
2,812,749
Derivative Exercise and Retained Stock
-
Form 4
-
Dec-04-2019
Common Stock
50,000
2,764,464
Derivative Exercise and Retained Stock
-
Form 4
-
Dec-04-2019
Common Stock
38,000
2,358,901
Derivative Exercise and Retained Stock
-
Form 4
-
Dec-04-2019
Common Stock
30,000
2,187,293
Derivative Exercise and Retained Stock
-
Form 4
Klosk B.S., J.D., Steven M. (Former CEO & Director)
Dec-04-2019
Common Stock
(347,206)
(28,334,718)
Open Market Disposition
(100.00)
Form 4
Klosk B.S., J.D., Steven M. (Former CEO & Director)
Dec-04-2019
Common Stock
65,500
0
Other Acquisition
(100.00)
Form 4
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Hewett, Wayne M.
Chairman
201 804 3000
201 804 9852

Loewald, Thomas W.
CEO & Executive Director
201 804 3000
201 804 9852

Coyle, John 
Director
(212) 386-7480
201 804 9852
john.coyle@permira.com
Glassell, Claes 
Director
201 804 3000
201 804 9852

Minello, Henry
Director
212-386-7480
201 804 9852
-
O’Donnell, Laura 
Director
201 804 3000
201 804 9852
-
* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Loewald, Thomas W.
CEO & Executive Director
201 804 3000
201 804 9852

Green, Robert Charles
Executive VP & CFO
201 804 3000
201 804 9852

Hanley, Samantha M.
Senior VP, General Counsel & Corporate Secretary
201 804 3000
201 804 9852
samantha.hanley@cambrex.com
Maw, Alex 
Senior Director of Marketing & Communications
(447) 803-4431x55
201 804 9852
alex.maw@cambrex.com
Brienza, Dorothy Donnelly
Senior VP & Chief Human Resources Officer
201 804 3000
201 804 9852

Biscaro, Bruno 
President of Drug Products
201 804 3000
201 804 9852
-
Edwards, Simon 
President of CDMO Sales & Marketing
201 804 3000
201 804 9852
-
Ferrante, Frank 
Chief Mergers & Acquisitions Officer
201 804 3000
201 804 9852

Fincher, Brandon 
Chief Strategy Officer
201 804 3000
201 804 9852

Haitz, Stephan 
President of CDMO Sales & Marketing
201 804 3000
201 804 9852
-
Nettleton, Joe 
President of Drug Substance
201 804 3000
201 804 9852
-
Player, Troy 
President of Early Stage Development & Testing
201 804 3000
201 804 9852

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
